114 related articles for article (PubMed ID: 26683629)
1. Experience with the Histrelin Implant in Pediatric Patients.
Eugster EA
Endocr Dev; 2016; 30():54-9. PubMed ID: 26683629
[TBL] [Abstract][Full Text] [Related]
2. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
3. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis D; Karavani G; Hirsch HJ; Strich D
J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
[TBL] [Abstract][Full Text] [Related]
4. A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
Lewis KA; Goldyn AK; West KW; Eugster EA
J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA
J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268
[TBL] [Abstract][Full Text] [Related]
6. Resumption of puberty in girls and boys following removal of the histrelin implant.
Fisher MM; Lemay D; Eugster EA
J Pediatr; 2014 Apr; 164(4):912-916.e1. PubMed ID: 24433825
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
[TBL] [Abstract][Full Text] [Related]
8. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.
Lewis KA; Eugster EA
J Pediatr; 2013 Mar; 162(3):562-5. PubMed ID: 23040793
[TBL] [Abstract][Full Text] [Related]
9. Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty.
Davis JS; Alkhoury F; Burnweit C
J Pediatr Surg; 2014 May; 49(5):807-10. PubMed ID: 24851775
[TBL] [Abstract][Full Text] [Related]
10. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
[TBL] [Abstract][Full Text] [Related]
11. Histrelin for central precocious puberty-a single surgeon experience.
Rosati S; Maarouf R; Brown K; Poppe M; Parrish D; Haynes J; Lanning D
J Surg Res; 2015 Oct; 198(2):355-9. PubMed ID: 25899147
[TBL] [Abstract][Full Text] [Related]
12. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.
Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028
[TBL] [Abstract][Full Text] [Related]
13. Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty.
Ray LA; Eckert GJ; Eugster EA
J Pediatr Endocrinol Metab; 2023 Mar; 36(3):309-312. PubMed ID: 36625262
[TBL] [Abstract][Full Text] [Related]
14. Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty.
Barradell LB; McTavish D
Drugs; 1993 Apr; 45(4):570-88. PubMed ID: 7684676
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database.
Silverman LA; Han X; Huang H; Near AM; Hu Y
J Pediatr Endocrinol Metab; 2021 Aug; 34(8):961-969. PubMed ID: 34147047
[TBL] [Abstract][Full Text] [Related]
16. Intraoperative sonographic localization of a fractured Supprelin implant in a pediatric patient: a case report.
Monroe BJ; Fallon SC; Brandt ML
J Pediatr Endocrinol Metab; 2012; 25(1-2):167-9. PubMed ID: 22570970
[TBL] [Abstract][Full Text] [Related]
17. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
[TBL] [Abstract][Full Text] [Related]
18. Optimizing pediatric histrelin implantation to improve success rates in clinic without sedation.
Krishna V; Lee SL; DeUgarte DA
J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1443-1448. PubMed ID: 34407329
[TBL] [Abstract][Full Text] [Related]
19. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
[TBL] [Abstract][Full Text] [Related]
20. Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty.
Lewis KA; Eugster EA
Drug Des Devel Ther; 2009 Sep; 3():1-5. PubMed ID: 19920916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
